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ObesityObjectives: Conﬂicting evidence concerning leptin in atherosclerosis has been published. Furthermore, dose-
dependent effects of leptin on atherogenesis have not been studied.
Methods: Leptin-deﬁcient low-density lipoprotein receptor (LDLR) knockout (LDLR−/−;ob/ob)micewere treated
with saline, 0.1, 0.5, or 3.0 mg/kg body weight (BW)/d recombinant leptin over 12 weeks starting at 8 weeks of
age. Aortic root and brachiocephalic artery (BCA) atherosclerotic lesionswere analyzed by oil red O staining. Fur-
thermore, glucose homeostasis, lipid metabolism, and liver function including tissue studies were assessed in all
animals.
Results: Leptin treatment dose-dependently decreased BW in LDLR−/−;ob/obmice as compared to saline. Mice in
the 0.1 and 0.5mg/kg BW/d groups remainedheavier (i.e. subphysiological leptin dose) and in the 3.0mg/kg BW/
d group had similar weight (i.e. physiological leptin dose) as compared to non-leptin-deﬁcient LDLR−/− animals.
Recombinant leptin dose-dependently reduced plaque area in the aortic root and the BCA by 36% and 58%,
respectively. Leptin-mediated reductions of plasma total and LDL-cholesterol (Chol) remained independent
predictors for aortic root plaque area. Chol content in liver, as well as hepatic expression of key lipid and
proinﬂammatory genes, were dose-dependently regulated by leptin. Furthermore, leptin treatment increased
circulating levels and adipose tissue mRNA expression of the adipokine adiponectin.
Conclusions: Leptin administration within the subphysiological to physiological range diminishes atherosclerotic
lesions. Leptin appears to mediate its antiatherogenic effects indirectly through reduction of hypercholesterol-
emia and liver steatosis, as well as upregulation of insulin-sensitizing and atheroprotective adiponectin.
© Published by Elsevier B.V.20151. Introduction
Atherosclerosis is a lipid-driven chronic inﬂammatory disease and
the main cause of cardiovascular morbidity and mortality. It has been
recognized that obesity which is associated with an expansion of
adipose tissue is a predisposing risk factor for atherosclerosis [1].
Adipose tissue has pleiotropic effects beyond energy storage and
functions as an endocrine organ that secretes various bioactive
molecules [2]. Proteins that are secreted by adipose tissue and that
provide an extensive network of para- and endocrine communication
are collectively called adipokines [3].
Among those, leptin is a 16 kDa adipokine which is dysregulated in
obesity and inﬂuences appetite and body weight (BW) [4,5]. The
adipokine is transported across the blood–brain barrier where it binds, Germany.
(S. Kralisch).to speciﬁc receptors of appetite-modulating neurons most notably in
the hypothalamus [6]. In accordance with an appetite-suppressive
effect, leptin-deﬁcient ob/obmice, as well as human subjects, develop
severe hyperphagia and excessive morbid obesity associated with dys-
lipidemia, fatty liver disease, insulin resistance (IR), hyperinsulinemia,
and diabetes mellitus type 2 [7,8]. Administration of recombinant leptin
in leptin-deﬁcient mice and humans reduces food intake, BW, and fat
mass [9,10].
Whereas leptin has been well-established as an appetite-
suppressive adipokine, its role in vascular disease is far from clear
since conﬂicting data have been published. Thus, various independent
studies suggest that the adipokine has antiatherogenic properties.
Among those, Lloyd and co-workers have shown convincingly that leptin
treatment ameliorates atherosclerotic disease in atherosclerosis-prone
apolipoprotein (Apo) E triple-knockout- (ApoE−/−;ApoB48−/−;ob/ob)
and low-density lipoprotein receptor (LDLR) triple-knockout
(LDLR−/−;ApoB48−/−;ob/ob) mice [11]. Furthermore, leptin inhibited
the progression of atherosclerosis in type 1 diabetic ApoE−/−;
Ins2+/Akita mice by attenuating hypercholesterolemia [12]. In addition,
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accelerated IR-associated atherosclerosis and dyslipidemia as compared
to LDLR−/− controls [13,14]. In contrast to these ﬁndings, leptin
treatment increased atherosclerosis and shortened the time to occlusive
thrombosis after vascular injury [15]. Similarly, Zeadin and co-workers
convincingly demonstrated that leptin-treated animals were character-
ized by an increase in lesion calciﬁcation, as well as valvular calciﬁca-
tion, as compared to vehicle-treated controls [16]. Furthermore, daily
administration of recombinant leptin to ob/ob mice over 3 weeks
after carotid artery injury with ferric chloride dramatically increased
neointimal thickness and the severity of luminal stenosis [17].
Taking these studies into consideration, leptin appears to have both
pro- and antiatherogenic effects whichmight depend on the dose of the
adipokine used. However, to the best of our knowledge dose-dependent
effects of leptin on atherogenesis have not been assessed so far. Further-
more, it remains unclear which metabolic parameters predict the im-
pact of the adipokine on vascular disease. To address these open
points, atherosclerosis-prone and leptin-deﬁcient LDLR−/−;ob/obmice
were treated in the current study with three increasing ﬁxed doses of
recombinant mouse leptin. Leptin doses ranged from subphysiological
levels, i.e. doses not sufﬁcient to normalize BW, to physiological levels,
i.e. doses sufﬁcient to normalize BW to LDLR−/− control levels. We
hypothesized that within this subphysiological to physiological range,
leptin has potent antiatherogenic effects in LDLR−/−;ob/obmice which
are mediated through improved metabolic function.Fig. 1. (A) BW (N ≥ 19 per group LDLR−/−;ob/ob; N= 8 LDLR−/−), (B) fat mass (N ≥ 9 per grou
treated LDLR−/−;ob/obmice. Statistical analysiswas performed by one-way ANOVA of (A) AUC
means ± standard error. P b 0.05 as compared to 1saline; 20.1 mg leptin/kg BW/d; 30.5 mg lep2. Materials and methods
2.1. Animal care
The local ethics committee (Landesdirektion Sachsen, Leipzig) of the
state of Saxony approved the protocol of all animal experiments
(approval no. TVV37/12). Breeding and husbandry of homozygous
male LDLR knockout and leptin-deﬁcient (LDLR−/−;ob/ob) mice was
done in our local animal facility, the Medical Experimental Center of
the University of Leipzig. All mice were maintained in a room under
pathogen-free conditions with controlled 21 ± 1 °C on a 12:12 h light/
dark cycle (6 AM/6 PM). Water and chow pellet diet (V1534 from
Sniff, Soest, Germany) was provided ad libitum until age of 4 weeks.
2.2. Animal treatment
LDLR−/−;ob/obmicewere fed ad libitumwith amodiﬁed, cholester-
ol (Chol)-enriched semisynthetic Clinton/Cybulsky diet (Sniff, Soest,
Germany) starting at the age of 4weeks. At 8weeks of age, bodyweight
(BW)-matched mice were separated into four groups and treated
daily over a period of 12 weeks i.p. with saline or increasing concentra-
tions of recombinant mouse leptin (0.1 mg/kg BW, 0.5 mg/kg BW, and
3.0 mg/kg BW) (R&D Systems, Wiesbaden—Nordenstadt, Germany).
At 20 weeks of age, mice were sacriﬁced by exsanguination under
deep anesthesia.p), and (C) leanmass (N ≥ 9 per group) over the course of treatment in leptin- and saline-
or (B, C) raw data corrected formultiple testing by Bonferroni–Holm. Data are presented as
tin/kg BW/d.
Fig. 2.Dose-dependent effects of recombinant leptin (0.1, 0.5, and 3.0mg/kg BW/d) as compared to saline on (A) aortic root plaque area (N ≥ 19per group), (B) BCAplaque area (N ≥ 10per
group), and (C) BCAmacrophage inﬁltration (N ≥ 8 per group). Lesion size analyses and immunostaining for CD68were performed as further described inMaterials andMethods. Data are
presented asmeans± standard error. Differenceswere assessed by one-way ANOVA corrected by Bonferroni–Holm. ⁎indicates P b 0.05, ⁎⁎P b 0.01, ⁎⁎⁎P b 0.001. (D) Representative oil red
O (ORO)- and CD68-stained BCA sections in saline- and 3.0 mg/kg BW/d leptin-treated animals are shown. Scale bar, 200 μm.
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BW was recorded daily and whole body composition (fat mass and
lean mass) was determined in awake mice by using EchoMRI700
(Echo Medical Systems, Houston, TX) at 8, 14, and 20 weeks of age.
Alanine aminotransferase (ALT), aspartate aminotransferase (AST),
and glucose were analyzed by standard laboratory methods in a
certiﬁed laboratory. Plasma concentrations of insulin (Mercodia,Table 1
Glucose homeostasis, lipid metabolism, and liver function in LDLR−/−;ob/obmice treated over
alanine aminotransferase; AST, aspartate aminotransferase; BW, bodyweight; Chol, cholesterol
tance; LDL, low-density lipoprotein; TG, triglycerides; VLDL, very low-density lipoprotein; mea
30.5 mg leptin/kg BW/d using one-way ANOVA corrected by Bonferroni–Holm.
Saline
Leptin (m
0.1
Glucose homeostasis
Glucose (mmol/l) 23.2 ± 1.2 18.4 ±
Insulin (μg/l) 3.3 ± 0.5 1.0 ±
HOMA-IR 77.6 ± 11.0 19.5 ±
Lipid metabolism
Total TG (mg/dl) 784.7 ± 19.8 690.7 ±
Total Chol (mg/dl) 1693.7 ± 24.3 1547.8 ±
VLDL-TG (mg/dl) 605.8 ± 16.2 527.9 ±
VLDL-Chol (mg/dl) 537.7 ± 8.5 479.2 ±
LDL-TG (mg/dl) 154.1 ± 6.9 143.3 ±
LDL-Chol (mg/dl) 1050.6 ± 19.1 983.5 ±
HDL-TG (mg/dl) 24.9 ± 2.8 19.5 ±
HDL-Chol (mg/dl) 105.5 ± 7.3 85.1 ±
Liver function
AST (μkat/l) 7.3 ± 0.9 3.9 ±
ALT (μkat/l) 5.6 ± 0.4 3.5 ±Uppsala, Sweden) and adiponectin (Mediagnost, Reutlingen, Germany)
were measured by commercial ELISA systems according to the
manufacturers' instructions. Homeostasis model assessment of IR
(HOMA-IR) was calculated as previously described [18]. Lipoproteins
were isolated by sequential ultracentrifugation from 60 μl plasma at
densities (d) b 1.006 g/ml (very low-density lipoprotein [VLDL]),
1.006 ≤ d ≤ 1.063 g/ml (low-density including intermediate-density li-
poprotein [LDL]), and d N 1.063 g/ml (high-density lipoprotein [HDL])12 weeks i.p. with saline or recombinant leptin (0.1, 0.5, and 3.0 mg leptin/kg BW/d). ALT,
; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resis-
ns ± standard errors are shown. P b 0.05 as compared to 1saline; 20.1 mg leptin/kg BW/d;
g/kg BW/d)
0.5 3.0
0.71 20.4 ± 1.3 16.7 ± 1.21
0.11 0.5 ± 0.11,2 1.0 ± 0.31
2.31 12.7 ± 2.61 14.0 ± 3.81
48.1 487.0 ± 55.41 338.8 ± 54.11,2
65.4 1401.6 ± 79.2 1049.5 ± 83.21,2,3
39.9 363.8 ± 48.51 249.1 ± 47.81,2
31.3 394.4 ± 37.7 292.8 ± 41.81,2
10.2 106.2 ± 7.51,2 77.8 ± 7.31,2
36.1 911.5 ± 47.9 663.3 ± 47.61,2,3
2.2 17.0 ± 1.9 11.8 ± 1.51,2
4.3 95.7 ± 3.6 93.5 ± 5.11,2
0.9 2.8 ± 0.41 2.4 ± 0.51
0.4 1.8 ± 0.21,2 1.0 ± 0.31,2,3
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lipid fractions enzymatically by using a colorimetric method (Roche,
Mannheim, Germany).
Lipids were extracted from mouse liver tissue according to ref. 20
[20]. Liver Chol and TG content were assessed by a colorimetric assay
kit (Wako, Neuss, Germany).
2.4. Quantiﬁcation and characterization of atherosclerotic lesions
The extent of atherosclerosis in the aortic root and brachiocephalic
artery (BCA) was determined in a blinded fashion as recently described
[21,22]. In brief, aortic lesions were quantiﬁed in ﬁve equidistant
(200 μm) oil red O-stained sections in the region beginning at the
end of the aortic sinus and extending into the ascending aorta [21].
Furthermore, atherosclerotic lesions lumenal to the internal elasticFig. 3. Effect of leptin treatment on hepatic function in vivo. Hepatic (A) TG and (B) Chol conten
mice treatedwith saline or 0.1, 0.5, and 3.0mg/kg BW/d recombinant leptin relative to 36B4 (N
ANOVA corrected by Bonferroni–Holm. ⁎indicates P b 0.05, ⁎⁎P b 0.01, ⁎⁎⁎P b 0.001, ⁎⁎⁎⁎P b 0.00lamina were quantiﬁed in three equidistant (200 μm) oil red O-
stained sections per BCA. For both aortic root and BCA, mean lesion
sizes in equidistant oil red O-stained sections were calculated for each
animal and included in further analyses. Macrophage content of BCA
lesions was determined by immunohistochemistry using speciﬁc
CD68-antibodies (Bio-Rad AbD Serotec GmbH, Puchheim, Germany).
All lesions were photographed and analyzed using AxioVision Rel 4.8,
KS400 image analysis, and ZEN 2012 blue edition 1.1.1.0 (all Carl Zeiss
Microscopy GmbH, Jena, Germany).
2.5. Quantitative real-time RT-PCR analysis
Acetyl-CoA-carboxylase-1 (ACC-1), adiponectin (Adipo), 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR), monocyte chemoattractant
protein-1 (MCP-1), and tumor necrosis factor (TNF)αmRNA expressiont, as well as (C–F) mRNA expression of (C) ACC-1, (D) HMGCR, (E)MCP-1, and (F) TNFα in
≥ 7). Data are presented asmeans± standard error. Differences were assessed by one-way
01.
Table 2
Univariate correlationswith aortic root plaque area in all animals andmultivariate regres-
sion analysis between plaque area (dependent variable) and fat mass (lg), total Chol (lg),
LDL-TG, and ALT (lg). For covariates (e.g. total Chol and LDL-Chol), only the parameter
with the strongest association inunivariate analysiswas included in themultivariatemod-
el. Non-normally distributed variables were logarithmically transformed (lg) prior to uni-
and multivariate testing. r- and P-values, as well as standardized β-coefﬁcients and P-
values are given, respectively. Abbreviations are indicated in Table 1. *indicates signiﬁcant
correlation as assessed by Pearson's correlation method. †indicates signiﬁcant correlation
in multivariate analysis.
Univariate correlations
Multivariate
regression analysis
r/P β P
BW (g, lg) 0.492/b0.001* – –
Fat mass (%, lg) 0.565/b0.001* 0.219 0.267
Lean mass (%, lg) 0.132/0.267 – –
Glucose (mmol/l) 0.130/0.274 – –
Insulin (μg/l, lg) 0.162/0.163 – –
HOMA-IR (lg) 0.184/0.118 – –
Total TG (mg/dl, lg) 0.486/b0.001* – –
Total Chol (mg/dl, lg) 0.587/b0.001* 0.309 0.035†
VLDL-TG (mg/dl, lg) 0.460/b0.001* – –
VLDL-Chol (mg/dl, lg) 0.517/b0.001* – –
LDL-TG (mg/dl) 0.565/b0.001* 0.233 0.136
LDL-Chol (mg/dl, lg) 0.582/b0.001* – –
HDL-TG (mg/dl, lg) 0.266/0.022* – –
HDL-Chol (mg/dl, lg) −0.076/0.522 – –
AST (μkat/l, lg) 0.060/0.704 – –
ALT (μkat/l, lg) 0.454/b0.001* −0.011 0.952
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ﬂuorescent temperature cycler (Roche, Heidelberg, Germany) as
described previously [23]. Primers sequences used are summarized in
Supplemental Table 1.
2.6. Data analysis and statistics
Data sets were analyzed using Statistical Package for Social Sci-
ence, version 20 (SPSS 20; IBM, Armonk, NY) and GraphPad Prism
6 (GraphPad Software, San Diego, CA). Statistical signiﬁcance was
assessed as indicated in the table and ﬁgure legends. A P-value b 0.05
was considered as statistically signiﬁcant in all analyses.
3. Results
3.1. Leptin dose-dependently reduces atherosclerotic disease
Recombinant leptin treatment starting at 8 weeks of age dose-
dependently decreased BW in LDLR−/−;ob/ob mice as compared to
saline over the course of 12 weeks (Fig. 1A). At 20 weeks of age,
LDLR−/−;ob/obmice treated with 3.0 mg/kg BW/d had similar weight
(physiological leptin dose) whereas the groups treated with 0.1 and
0.5 mg/kg BW/d remained heavier (subphysiological leptin dose) as
compared to non-leptin-deﬁcient LDLR−/− animals (Fig. 1A). Leptin-
mediated decreased BW was due to changes in fat mass (Fig. 1B) but
not lean mass (Fig. 1C).
Recombinant leptin reduced plaque area in the aortic root
with a most pronounced and signiﬁcant 36% reduction observed
at 3.0 mg/kg BW/d as compared to control mice (P b 0.001)
(Fig. 2A). Similarly, leptin treatment signiﬁcantly reduced lesion size
in the BCA with a signiﬁcant 58% decrease seen in the 3.0 mg/kg BW/d
group as compared to saline-treated controls (P b 0.001) (Fig. 2B, D). Le-
sion size was signiﬁcantly and negatively correlated to leptin dose for
both aortic root and BCA (P b 0.05, data not shown). Furthermore,
lesional macrophages as determined by CD68-positive plaque area
was signiﬁcantly lower in mice treated with 3.0 mg/kg BW/d leptin
(0.30 ± 0.10 × 105 μm2) as compared to saline-treated animals
(0.70 ± 0.13 × 105 μm2) (P b 0.05) (Fig. 2C, D). However, there was
no signiﬁcant difference in CD68-positive plaque area relative to
whole plaque area between the different treatment groups (data not
shown).
3.2. Leptin improves glucose homeostasis, lipid metabolism, and liver
function
After 12 weeks of treatment, glucose homeostasis parameters in-
cluding fasting glucose, insulin, and HOMA-IR signiﬁcantly improved
with recombinant leptin as compared to saline (Table 1). Similarly,
lipidmetabolism, i.e. plasma TG andChol, aswell as TG and Chol content
in VLDL, LDL, and HDL dose-dependently and signiﬁcantly decreased in
leptin-treated animals as compared to controls (Table 1). Concomitant
with the decrease in circulating TG and Chol, leptin treatment
signiﬁcantly improved hepatic TG (Fig. 3A) and Chol (Fig. 3B) content
(P b 0.05). Furthermore, leptin treatment signiﬁcantly improved liver
function with lower AST and ALT seen in mice treated with the
adipokine (Table 1).
To identify potential mechanisms underlying the effect of leptin
treatment, hepatic expression of key genes involved in lipidmetabolism
was analyzed. HepaticmRNA expression of ACC-1which is a key regula-
tor of fatty acid synthesis was signiﬁcantly down-regulated by more
than 40% in leptin-treated animals (0.1 and 3.0 mg leptin/kg BW/d) as
compared to saline-treated mice (P b 0.05) (Fig. 3C). Similarly, the
rate-limiting enzyme for Chol biosynthesisHMGCRwas signiﬁcantly de-
creased in leptin-treated animals as compared to controls (P b 0.05)
(Fig. 3D). Hepatic mRNA expression of the proinﬂammatory cytokines
MCP-1 (Fig. 3E) and TNFα (Fig. 3F) was signiﬁcantly down-regulatedby more than 70% in animals treated with 3.0 mg leptin/kg BW/d as
compared to saline controls (P b 0.001). In addition, further key genes
involved in fatty acid synthesis and transport (fatty acid synthase,
CD36), in lipoproteinmetabolisms (hepatic triglyceride lipase, lipoprotein
lipase, ApoA-IV), in lipoprotein clearance (VLDL receptor), in ﬁbrosis
(transforming growth factor [TGF] β), and in inﬂammation (chemokine
[C–X–C motif] ligand 1[Cxcl1]) were signiﬁcantly regulated by leptin
treatment as compared to controls (Supplemental Figure 1).
3.3. Changes in total Chol predict effects of leptin on atherosclerotic disease
Atherosclerotic lesion size at the aortic root was positively and sig-
niﬁcantly correlated with BW, fat mass, total TG, total Chol, VLDL-TG,
VLDL-Chol, LDL-TG, LDL-Chol, HDL-TG, and ALT in all animals in univar-
iate analysis (P b 0.05) (Table 2). Multivariate regression analysis
revealed that total Chol remained independently and positively
associated with aortic root plaque area after adjustment for fat mass,
LDL-TG, and ALT (P = 0.035) (Table 2). In addition, LDL-Chol (β =
0.319; P = 0.026) remained signiﬁcantly and independently associated
with aortic root plaque area when included in the multivariate model
instead of total Chol.
3.4. Adiponectin is dose-dependently increased by leptin treatment
Plasma adiponectin levels were signiﬁcantly increased by leptin
treatment in a dose-dependent fashion from 6.7 mg/l (saline control)
to 8.5 mg/l (0.1 mg/kg BW/d; P b 0.05), 9.1 mg/l (0.5 mg/kg BW/d; P b
0.01), and 10.7 mg/l (3.0 mg/kg BW/d; P b 0.001), respectively
(Fig. 4A). Leptin-mediated increased circulating adiponectin was
accompanied by upregulated mRNA expression of the adipokine in
epididymal (Fig. 4B), subcutaneous (Fig. 4C), epirenal (Fig. 4D), and
epicardial (Fig. 4E) but not brown (Fig. 4F) adipose tissue.
4. Discussion
In the current study, we show for the ﬁrst time that leptin adminis-
tration within the subphysiological to physiological range reduces ath-
erosclerotic lesions in mice. All leptin concentrations used signiﬁcantly
decrease BW of LDLR−/−;ob/ob mice. The 3.0 mg/kg BW/d dosage
Fig. 4.Effect of leptin treatment (0.1, 0.5, and 3.0mg/kg BW/d) on (A) circulating adiponectin (N ≥ 19 per group) and (B–F) adiponectinmRNAexpression relative to 36B4 (N ≥ 6 per group)
in (B) epididymal (Epidy AT), (C) subcutaneous (SAT), (D) epirenal (Epir AT), (E) epicardial (Epic AT), and (F) brown (BAT) adipose tissue. Data are presented as means± standard error.
Differences were assessed by one-way ANOVA corrected by Bonferroni–Holm. ⁎indicates P b 0.05, ⁎⁎P b 0.01, ⁎⁎⁎P b 0.001, ⁎⁎⁎⁎P b 0.0001.
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whereas the 0.1 and 0.5 mg/kg BW/d groups have a BW between
LDLR−/−;ob/ob and LDLR−/− animals (subphysiological dose) at
20weeks of age. It is interesting to note in this context thatmost studies
demonstrating beneﬁcial effects of leptin on atherogenesis have also ad-
ministered leptin in the subphysiological to physiological range. Thus,
Lloyd and co-workers adjust all leptin doseswithin the subphysiological
range to maintain but not normalize BW in ApoE−/−;ApoB48−/−;ob/ob
and LDLR−/−;ApoB48−/−;ob/obmice [11]. In their hands, recombinant
leptin doses with beneﬁcial effects on atherogenesis range from 0.02
to 0.12 mg/kg BW/d [11]. Similarly, a low dose of 0.4 mg/kg BW/d
leptin inhibits progression of atherosclerosis in type 1 diabetic ApoE−/
−;Ins2+/Akita mice [12]. In contrast, most reports demonstratingproatherogenic effects of recombinant leptin use higher doses of the
adipokine as compared to these reports and our current study. Thus,
the two studies demonstrating increased lesion size [15], as well as
lesion calciﬁcation [16], in ApoE−/− mice use recombinant leptin at
125 μg/d. These published ﬁndings and our current results are in agree-
ment with the hypothesis that the effect of leptin on atherogenesis is
dose-dependent.
Mechanisms bywhich subphysiological to physiological leptin doses
improve atherogenesis have been further assessed in the current study
and in published reports. Our data and published evidence suggest that
leptin mediates its antiatherogenic effects indirectly through induction
of better metabolic control in leptin-deﬁcient states. Thus, leptin dose-
dependently improves parameters of glucose homeostasis, lipid
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Chol and LDL-Chol remain independent and positive predictors of aortic
root lesion size. These ﬁndings are in agreement with independent
studies in LDLR−/−;ApoB48−/−;ob/ob and ApoE−/−;ApoB48−/−;ob/ob
[11], as well as type 1 diabetic ApoE−/−;Ins2+/Akita [12], mice where
reduction in atherosclerotic lesion size is closely linked to improved
plasma Chol concentrations. Leptin-mediated improvements in Chol
metabolism are accompanied by decreased hepatic Chol content, as
well as mRNA expression of the rate-limiting enzyme in Chol synthesis
HMGCR, in the current study similar to published reports [24–26].
Furthermore, leptin reduces local hepatic inﬂammation by down-
regulation of proinﬂammatory cytokines including MCP-1, TNFα, and
Clxc1, as well as the ﬁbrosis marker TGFβ. Steatosis and associated
inﬂammation, as well as ﬁbrosis, are independent predictors of
occurrence and progression of atherosclerosis [27,28]. Taking these
ﬁndings into consideration, improved hepatic cholesterol metabolism
appears as a key factor contributing to the antiatherogenic effects of
subphysiological to physiological doses of leptin. Furthermore, nitric
oxide release triggered by leptin that counteracts in part the sympathet-
ic activation might be an additional mechanism for the antiatherogenic
effects of the adipokine at subphysiological to physiological concentra-
tions [29]. Moreover, the lipolytic effect of leptin which is located at
the adenylate cyclase/Gi proteins level and opposes the tonic inhibition
of endogenous adenosine in white fat cells might also contribute to de-
creased atherogenesis in leptin-treated animals [30]. Clearly,morework
is needed to better elucidatemechanisms for the antiatherogenic effects
of subphysiological to physiological concentrations of the adipokine
leptin.
In the current study, leptin increases circulating levels of the
adipokine adiponectin besides its beneﬁcial effects on lipid metabolism.
Elevated plasma adiponectin levels are probably caused by induced
mRNA expression of the adipokine in epididymal, subcutaneous,
epirenal, and epicardial adipose tissue. Adiponectin possesses potent
antiatherogenic activities which are mediated through its vasodilator,
antiapoptotic, anti-inﬂammatory, and antioxidative activities in cardiac
and vascular cells [31]. Furthermore, adiponectin decreases IR in
insulin-sensitive tissues including muscle, adipose tissue, and liver [3].
Elevation of circulating adiponectin by either adenoviral-mediated or
transgenic overexpression decreases atherogenesis in ApoE−/− mice
[32,33]. Taking these results into consideration, the atheroprotective
effects of subphysiological to physiological leptin doses might be
mediated in part by induction of adiponectin.
It needs to be pointed out that our study does not rule out direct
proatherogenic effects of leptin especially at supraphysiological doses.
It is interesting to note in this context that two studies demonstrating
proatherogenic effects of leptin use the adipokine at higher doses as
compared to our study, i.e. 125 μg/d [15,16]. Mechanisms bywhich lep-
tin might induce atherogenesis include activation of the sympathetic
nervous system, stimulation of cholesterol esters accumulation in
foam cells, upregulation of proinﬂammatory cytokines, chemokines,
and reactive oxygen species, as well as induction of endothelin-1, plate-
let hyperaggregability, and vascular smooth muscle cell hypertrophy
[34,35]. Furthermore, leptin and its receptor are expressed within
mice and human atherosclerotic plaques [36,37]. Moreover, convincing
evidence has been presented that at high concentrations leptin in-
creases the levels of other cardiovascular risk factors such as circulating
ﬁbrinogen [38]. Based on these studies and our current ﬁndings, it can
be hypothesized that subphysiological to physiological concentrations
of leptin are atheroprotective by indirect mechanisms whereas leptin
at higher doses might have direct proatherogenic effects. However,
two well-controlled studies also demonstrate proatherogenic effects of
leptin at lower doses [17,39]. Clearly,morework is needed to better elu-
cidatemechanisms for pro- and antiatherogenic effects of the adipokine
leptin.
Taken together, leptin administrationwithin the subphysiological to
physiological range diminishes atherosclerotic disease. Leptin appearsto mediate its antiatherogenic effects indirectly through reduction of
hypercholesterolemia and liver steatosis, as well as upregulation of
insulin-sensitizing and atheroprotective adiponectin.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.10.022.
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